

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human TRAIL R2/TNFRSF10B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or rhDcR3.
Source	Monoclonal Mouse IgG ₁ Clone # 71903
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B Met1-Glu182 Accession # CAG46696
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Agonist Activity Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which transduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.